On the fly News and insights, exclusive to thefly.com

AMRN

Amarin

$24.12

1.12 (4.87%)

17:24
12/13/19
12/13
17:24
12/13/19
17:24

Amarin raises guidance after FDA approves Vascepa

Amarin (AMRN) shares rallied almost 5% in intraday trading on Friday before they were halted, news pending. After the market closed, the FDA announced it approved the use of Vascepa as an adjunctive therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels of 150 milligrams per deciliter or higher. The statement added that Vascepa was the first FDA approved drug to reduce cardiovascular risk among patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy. Shortly afterward, Amarin confirmed the FDA announcement, raised its FY19 revenue guidance, and gave FY20 revenue guidance. The company raised its FY19 revenue view to $410M-$425M from $380M-$420M, against a consensus of $410.25M, and gave FY20 revenue guidance of $650M-$700M, against a consensus of $654.55M. The company said, "Amarin is providing this projected revenue guidance for 2020 and has based its projection on a number of factors, including, but not limited to, expectations on market acceptance of the newly expanded label for Vascepa and current plans for expanded promotion. Vascepa revenues are anticipated to continue to increase in 2020, accompanied by quarterly industry variability, including recurring seasonal factors, particularly in the first quarter... Beyond 2020, Amarin believes that Vascepa total net revenue will grow to reach multiple billions of dollars. "

  • 28

    Dec

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.